Overview

Non-Insulin Therapies for Diabetes Market Overview:

FutureWise Market Research has instantiated a report that provides an intricate analysis of Non-Insulin Therapies for Diabetes Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of the market.

According to the research study conducted by FutureWise research analysts, the market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the Non-Insulin Therapies for Diabetes Market along with the growth opportunities present across this business vertical.

Major players included in the Non-Insulin Therapies for Diabetes Market are:    
• GSK    
• ELI LILLY.      
• SUMITOMO DAINIPPON PHARMA    
• INTARCIA THERAPEUTICS  
• JIANGSU HANSOH PHARMACEUTICAL
• NOVO NORDISK
• EMISPHERE
• UNI-BIO SCIENCE GROUP
• Takeda
(Note: The list of the major players will be updated with the latest market scenario and trends)

Non-Insulin Therapies for Diabetes Market Segmentation:
By Type
• Alpha-glucosidase Inhibitors
• Amylin Agonists
• Biguanides
• Dipeptidyl Peptidase-4 (DPP4) Inhibitors
• Glinides / Meglitinides
• GLP-1 Analogs / GLP-1 Agonists
• Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
• Sulfonylureas
• Thiazolidinediones
• Others
By Application
• Monitoring
• Diagnosis
• Treatment
• Others.
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Non-Insulin Therapies for Diabetes Market by type, by application and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and the Middle East and Africa
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
    2.1. Research Data 
         2.1.1. Secondary Data
                2.1.1.1. Key Data from Secondary Sources
         2.1.2. Primary Data
                2.1.2.1. Key Data from Primary Sources
    2.2. Market Size Estimation 
    2.3. Market Breakdown and Data Triangulation 
    2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Non-Insulin Therapies for Diabetes Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Type Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Non-Insulin Therapies for Diabetes Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Non-Insulin Therapies for Diabetes Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Type Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Type Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Non-Insulin Therapies for Diabetes Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Alpha-glucosidase Inhibitors
   7.2. Amylin Agonists
   7.3. Biguanides
   7.4. Dipeptidyl Peptidase-4 (DPP4) Inhibitors
   7.5. Glinides / Meglitinides
   7.6. GLP-1 Analogs / GLP-1 Agonists
   7.7. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
   7.8. Sulfonylureas
   7.9. Thiazolidinediones
   7.10. Others

8. Non-Insulin Therapies for Diabetes Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Monitoring
   8.2. Diagnosis
   8.3. Treatment
   8.4. Others

9. North America Non-Insulin Therapies for Diabetes Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   9.1. Introduction
   9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
        9.2.1. U.S.A
        9.2.2. Canada
        9.2.3. Mexico
   9.3. Market Size (USD Million) Forecast for North America 2022-2028

10. Latin America Non-Insulin Therapies for Diabetes Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. Brazil
          10.2.2. Venezuela
          10.2.3. Argentina
          10.2.4. Rest of Latin America
    10.3. Market Size (USD Million) Forecast for Latin America 2022-2028

11. Europe Non-Insulin Therapies for Diabetes Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Germany
          11.2.2. U.K         
          11.2.3. France
          11.2.4. Italy
          11.2.5. Spain
          11.2.6. Russia
          11.2.7. Poland
          11.2.8. Rest of Europe
    11.3. Market Size (USD Million) Forecast for Europe 2022-2028

12. Asia Pacific Non-Insulin Therapies for Diabetes Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Japan
          12.2.2. China
          12.2.3. India
          12.2.4. Australia and New Zealand
          12.2.5. ASEAN
          12.2.6. Rest of Asia Pacific
    12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

13. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. GCC
          13.2.2. Israel
          13.2.3. South Africa
          13.2.4. Rest of MEA
    13.3. Market Size (USD Million) Forecast for MEA 2022-2028

14. Market Share Analysis and Competitive Landscape   
    14.1. Global Landscape - Key Players, Revenue and Presence
    14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    14.3. Global Emerging Companies
    14.4. North America - Market Share Analysis and Key Regional Players
    14.5. Europe - Market Share Analysis and Key Regional Players
    14.6. Asia Pacific - Market Share Analysis and Key Regional Players
    14.7. Global Key Player - Growth Matrix

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    15.1. GSK
          15.1.1. Company Overview
          15.1.2. Product Portfolio
          15.1.3. SWOT Analysis
          15.1.4. Financial Overview
          15.1.5. Strategic Overview
    15.2. ELI LILLY
          15.2.1. Company Overview
          15.2.2. Product Portfolio
          15.2.3. SWOT Analysis
          15.2.4. Financial Overview
          15.2.5. Strategic Overview                         
    15.3. SUMITOMO DAINIPPON PHARMA
          15.3.1. Company Overview
          15.3.2. Product Portfolio
          15.3.3. SWOT Analysis
          15.3.4. Financial Overview
          15.3.5. Strategic Overview
    15.4. INTARCIA THERAPEUTICS
          15.4.1. Company Overview
          15.4.2. Product Portfolio
          15.4.3. SWOT Analysis
          15.4.4. Financial Overview
          15.4.5. Strategic Overview
    15.5. JIANGSU HANSOH PHARMACEUTICAL
          15.5.1. Company Overview
          15.5.2. Product Portfolio
          15.5.3. SWOT Analysis
          15.5.4. Financial Overview
          15.5.5. Strategic Overview          
    15.6. NOVO NORDISK
          15.6.1. Company Overview
          15.6.2. Product Portfolio
          15.6.3. SWOT Analysis
          15.6.4. Financial Overview
          15.6.5. Strategic Overview      
    15.7. EMISPHERE
          15.7.1. Company Overview
          15.7.2. Product Portfolio
          15.7.3. SWOT Analysis
          15.7.4. Financial Overview
          15.7.5. Strategic Overview
    15.8. UNI-BIO SCIENCE GROUP
          15.8.1. Company Overview
          15.8.2. Product Portfolio
          15.8.3. SWOT Analysis
          15.8.4. Financial Overview
          15.8.5. Strategic Overview 
    15.9. Takeda
          15.9.1. Company Overview
          15.9.2. Product Portfolio
          15.9.3. SWOT Analysis
          15.9.4. Financial Overview
          15.9.5. Strategic Overview 

16. Pre and Post COVID-19 Impact
    16.1. Positive influence on the healthcare industry
    16.2. The financial disruption of the manufacturing sector
    16.3. Impact of COVID-19 on emerging companies
    16.4. Significant mandates in the healthcare regulations initiated by administrations
    16.5. The overall economic slowdown of the developing and developed nations

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures